NeoGenomics

$54.34
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.35 (+2.55%) Today
$0.00 (0.00%) As of 11:01 PM UTC after-hours

Why Robinhood?

You can buy or sell NeoGenomics and other stocks, options, and ETFs commission-free!

About NEO

NeoGenomics, Inc. Common Stock, also called NeoGenomics, is a clinical laboratory company, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL. The listed name for NEO is NeoGenomics, Inc. Common Stock.

CEO
Douglas M. Van Oort
Employees
1,700
Headquarters
Fort Myers, Florida
Founded
1998
Market Cap
6.61B
Price-Earnings Ratio
Dividend Yield
Average Volume
846.73K
High Today
$55.97
Low Today
$51.03
Open Price
$53.00
Volume
995.54K
52 Week High
$61.57
52 Week Low
$20.47

NEO News

Benzinga11h

Recap: NeoGenomics Q4 Earnings

Shares of NeoGenomics (NASDAQ:NEO) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share rose 40.00% over the past year t

NEO Earnings

-$0.10
-$0.02
$0.06
$0.14
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
$0.06 per share
Actual
$0.14 per share
Replay Earnings Call

You May Also Like

REYN
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure